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BACKGROUND AND PURPOSE
Identifying and characterizing potential new therapeutic agents to target cell proliferation may provide improved treatments
for neoplastic disorders such as cancer and polycystic diseases.
EXPERIMENTAL APPROACH
We used the simple, tractable biomedical model Dictyostelium to investigate the molecular mechanism of naringenin, a
dietary flavonoid with antiproliferative and chemopreventive actions in vitro and in animal models of carcinogenesis. We then
translated these results to a mammalian kidney model, Madin-Darby canine kidney (MDCK) tubule cells, grown in culture and
as cysts in a collagen matrix.
KEY RESULTS
Naringenin inhibited Dictyostelium growth, but not development. Screening of a library of random gene knockout mutants
identified a mutant lacking TRPP2 (polycystin-2) that was resistant to the effect of naringenin on growth and random cell
movement. TRPP2 is a divalent transient receptor potential cation channel, where mutations in the protein give rise to type 2
autosomal dominant polycystic kidney disease (ADPKD). Naringenin inhibited MDCK cell growth and inhibited cyst growth.
Knockdown of TRPP2 levels by siRNA in this model conferred partial resistance to naringenin such that cysts treated with 3
and 10 μM naringenin were larger following TRPP2 knockdown compared with controls. Naringenin did not affect chloride
secretion.
CONCLUSIONS AND IMPLICATIONS
The action of naringenin on cell growth in the phylogenetically diverse systems of Dictyostelium and mammalian kidney cells,
suggests a conserved effect mediated by TRPP2 (polycystin-2). Further studies will investigate naringenin as a potential new
therapeutic agent in ADPKD.
LINKED ARTICLES
This article is part of a themed section on the pharmacology of TRP channels. To view the other articles in this section visit
http://dx.doi.org/10.1111/bph.2014.171.issue-10
Abbreviations
ADPKD, autosomal dominant polycystic kidney disease; PKD, polycystic kidney disease; PKD1, the gene-encoding
TRPP1 in humans; pkd1, the gene-encoding TRPP1 in Dictyostelium; PKD2, the gene-encoding TRPP2 in humans; pkd2,
the gene-encoding TRPP2 in Dictyostelium; pkd2−, the Dictyostelium mutant lacking the pkd2 gene
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Introduction
The development of new treatments for a disease requires
knowledge of the molecular target(s) of those treatments. The
social amoeba, Dictyostelium discoideum, is a simple biomedi-
cal model commonly used to study developmental and cel-
lular biology. Dictyostelium has recently been used in early
drug development studies (Chang et al., 2012) and to identify
molecular pathways regulating drug action (Terbach et al.,
2011). In its natural forest-floor habitat, Dictyostelium exists
in its amoeboid state and feeds on bacterial cells by phago-
cytosis (Williams et al., 2006). When nutrients are scarce, cells
aggregate to form fruiting bodies containing spores that are
dormant and resistant to desiccation. Growth and develop-
ment are controlled by a range of separate signalling path-
ways that can be probed at the molecular level by screening
libraries of insertional mutants, constructed by restriction
enzyme-mediated integration (REMI). This approach has pro-
vided new insights into how current therapeutic agents regu-
late cellular function (Williams et al., 2006), for example, in
identifying common signalling pathways targeted by lithium
and valproic acid in the treatment of bipolar disorder, and is
increasingly being used to identify cellular mechanisms con-
trolling drug targets using growth and development (Terbach
et al., 2011) or cell movement (Robery et al., 2011) as pheno-
typic readouts.
Naringenin (4′,5,7-trihydroxyflavanone; Figure 1) is a
member of the flavonone subclass of flavonoids, a large family
of plant polyphenols. Naringenin is ingested mostly as nar-
ingin (its glycoside) and is available at relatively high doses
(∼30 mg naringin 100 mL-1) in grapefruit juice (http://www
.phenol-explorer.eu). Naringenin is bioavailable after reason-
able doses; for example, a dose of 139–265 mg naringenin
yielded 0.7–14.8 μM of the aglycone in the blood after absorp-
tion (Erlund et al., 2001). After phase 2 metabolism, narin-
genin glucuronides and sulphates are detected in low
micromolar concentrations (Manach et al., 2005). In common
with many flavonoids, naringenin inhibits growth in tumour
cells by a number of mechanisms, including cell cycle arrest
and p53-dependent apoptosis (Meiyanto et al., 2012). Narin-
genin also suppresses colon cancer in rats (Leonardi et al.,
2010) and inhibits metastasis and tissue invasion (Weng and
Yen, 2012). The chemopreventive actions of naringenin may
include activation of certain cytochrome P450 isozymes and
phase 2 enzymes involved in the detoxification of potential
carcinogens (Moon et al., 2006; Kale et al., 2008).
Since a previous study had shown that naringenin
blocked Dictyostelium cell growth (Russ et al., 2006), we
sought to identify the molecular mechanism of naringenin
function in this model. By screening a library of Dictyostelium
REMI mutants, it was possible to identify genes conferring
resistance to naringenin. We then used the appropriate
mammalian system to study the role of the identified gene
product in mediating the actions of naringenin on cell
growth. Our data have identified a new candidate for
naringenin-mediated cell function: polycystin-2 (TRPP2), a
Ca2+ permeable non-selective cation channel implicated in
the development of autosomal dominant polycystic kidney
disease (ADPKD; González-Perrett et al., 2001; Vassilev et al.,
2001). In this disease, kidney cysts develop due to a defect in
proliferation and because of fluid secretion into the cysts
(Terryn et al., 2011). About 85% of ADPKD cases result from
mutations in the TRPP1 (polycystic kidney disease-1) gene
and protein, with the remainder accounted for by mutations
in the TRPP2 (PKD2) gene and protein (Chapin and Caplan,
2010). We therefore followed up on our own initial observa-
tions in Dictyostelium by studying the involvement of TRPP2
in the effects of naringenin on the growth of Madin-Darby
canine kidney (MDCK) cells and cysts. We found that TRPP2
(polycystin-2) mediated the growth-inhibitory effects of nar-
ingenin in both systems.
Methods
Dictyostelium growth assays
Dictyostelium discoideum wild-type cells (Ax2) were grown in
shaking suspension in Axenic medium (ForMedium Co. Ltd,
Norfolk, UK) at 120 rpm (21°C) and harvested in mid-log
phase (4 × 106). Cells (1 × 106 cells·mL−1) were then resus-
pended in Axenic medium containing 100 μM naringenin or
DMSO and counted at 24 h intervals.
Dictyostelium insertional mutagenesis
library screening
Dictyostelium wild-type cells (Ax4) were mutagenized by REMI
of plasmid DNA using pBBC plasmids, which are derivatives
of the pBSR1 plasmid (Adachi et al., 1994) that contain 60mer
DNA barcodes (C. Dinh, pers. comm.). REMI was performed
using three combinations of restriction enzymes for plasmid
linearization/electroporation (BamHI/DpnII, EcoRI/ApolI and
SphI/NlaIII). Clonal transformants were propagated in 24-well
culture plates and stored at –80°C in 10% DMSO for future
recovery. The residual cells from these plates were spotted on
a bacterial growth plate, allowed to grow for 2 days, and
collected as pools (24 mutants per pool). A number of these
pools of 24 (28–32 pools) were combined into 30 large pools
of 672–768 mutants. Twenty-five large pools were used in the
enrichment experiments that were carried out for each pool,
in triplicate, in 10 cm Petri dishes with 10 mL of HL-5 supple-
mented with 100 μg·mL−1 streptomycin and 100 U·mL−1
penicillin (Sussman, 1987). Naringenin (200 μM final con-
centration) was added to 5 × 106 mutant cells in 10 mL of
supplemented HL-5. After 3 days or when cell concentration
reached ∼2 × 106 cells·mL−1, 1 mL of the initial culture media
was removed and added to 9 mL of fresh media containing
Figure 1
Structure of naringenin (4′,5,7-trihydroxyflavanone).
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naringenin. The same procedure was repeated for 21 days.
Genomic DNA was purified from cells that were collected
from each culture dish and plasmid insertion sites were
cloned as described previously (Kuspa, 2006). After a mutant’s
insertion site was identified by plasmid rescue, a clonal strain
was recovered from the 24-well frozen stock to confirm resist-
ance to growth inhibition by naringenin and for further
analysis.
Dictyostelium pkd2− recapitulation
Knockout constructs were created using methods described
previously (Pakes et al., 2012). Briefly, 5′ and 3′ fragments
flanking the Dictyostelium pkd2 was amplified by PCR
(peqSTAR 96 Universal Gradient, Erlangen, Germany) from
wild-type genomic DNA. The 5′ terminal targeting fragment
was amplified using AAGGGATCCAATACCTTGAAATTAA
TAATCCATC and TTAACTGCAGCTGATGCTGTC, and the 3′
terminal fragment was amplified using CTGATATTGCCT
CATTCCATGGCTTCG and TTGGTGATTGTGGGGTACCAG
TAC. The 5′ and 3′ PCR fragments were cloned into the
plPBLP expression vector using BamHI/PstI (5′ fragment-
500 bp) and NcoI/KpnI (3′ fragment-744 bp) restriction sites,
respectively, incorporating the gene in the reverse orientation
to the blasticidin resistance cassette. The knockout cassette
was linearized and transformed into wild-type cells via elec-
troporation (Gene Pulser Xcell, Bio-Rad, Hertfordshire, UK).
Positive transformants were selected in nutrient media con-
taining blasticidin (10 μg·mL−1). Independent clones were
screened for homologous integration by PCR, using diagnos-
tic PCR products for the presence of target gene genomic
DNA and knockout vector sequences, as well as a diagnostic
PCR product only found for homologous intergrant for both
N and C-terminal regions of the knockout cassette. Triplicate
independent isolates were identified, clonally plated onto
Raoultella planticola, and isogenic colonies were used in sub-
sequent experiments.
Dictyostelium random cell movement assay
To analyse the effect of naringenin on Dictyostelium random
cell movement, wild-type and pkd2− cells were grown in
shaking suspension in Axenic medium for 48 h, washed and
resuspended in phosphate buffer at 1.7 × 106 cells·mL−1, and
treated with 30 nM cAMP at 6 min intervals while shaking at
120 rpm as described previously (Robery et al., 2011). Cells
were then shaken in the presence of 200 μM naringenin or
0.7% DMSO (solvent control) for 1 h, transferred into 8-well
glass coverslips (Thermo Fisher, Loughborough, UK) and
random cell movement was recorded by capturing one image
every 15 s for 5 min. A minimum of three independent
experiments were performed for each cell and condition,
whereby an average ∼10 cells were quantified per experiment.
Random cell movement was analysed using the Quimp 11b
software package for ImageJ (Tyson et al., 2010). Data were
imported into MATLAB where changes in motility, circularity,
distance travelled and number of protrusions formed were
monitored for each cell line in the presence and absence
naringenin. The effect of naringenin was assessed in relation
to distance travelled by cells during random cell movement,
cell circularity, number of protrusions and motility. Data were
compared using one-way ANOVA with Tukey’s post hoc test.
MDCK cell culture
MDCK C7 cells were a generous gift from Dr Anselm Zdebik
(Department of Neuroscience, Physiology & Pharmacology,
University College London). MDCK cells were cultured
in DMEM (Life Technologies, Ltd., Paisley, UK) contain-
ing 10% (v v-1) FBS, gentamycin (40 μg·mL−1), penicillin
(100 units·mL−1) and streptomycin (1040 μg·mL−1), and were
maintained at 37°C in a humidified, 5% CO2 atmosphere.
Cells of less than 18 passage numbers were used for all cyto-
toxicity and cyst growth studies.
MDCK cell viability assays
Naringenin was dissolved in DMSO (to a maximum of 0.1%
DMSO v v-1) and evaluated for its antiproliferative effect on
MDCK cells using the sulforhodamine B (SRB) assay. Cells
were seeded in complete DMEM in a 96-well plate (10 000
cells per well), allowed to adhere for 24 h then incubated
with naringenin (1–100 μM) for 24–48 h. The medium was
removed and 100 μL of SRB solution [0.4% (w/v) in 1% acetic
acid] was added to each well and plates were incubated for
10 min at room temperature. The SRB solution was removed
and cells were washed five times with 1% acetic acid (200 μL
per well) before air drying. SRB bound to adherent cells was
solubilized with 10 mM Tris base (unbuffered) and plates
were placed on a horizontal shaker for at least 10 min at
room temperature. Absorbance was read at 550 nm using an
ELx808 Absorbance Microplate reader (Biotek, Potton, UK).
Actinomycin-D (5 μM) was used as a positive control. The
neutral red assay was performed as described previously
(Repetto et al., 2008) with readings at 510 nm. EC50 values
were calculated by four-parameter non-linear regression
using GraphPad Prism (GraphPad Software, San Diego, CA,
USA).
MDCK cyst culture and measurement
For cyst growth studies, we followed a published protocol
(Li et al., 2004). In brief, MDCK cells were cultured in
24-well plates. A cell suspension (∼800 cells per well) was
mixed with 0.4 mL ice-cold collagen (PureCol, Nutacon BV,
Leimuiden, The Netherlands) supplemented with DMEM
containing 10% (v/v) FBS, gentamycin (40 μg·mL−1), penicil-
lin (100 units·mL−1), streptomycin (1040 μg·mL−1), 10 mM
HEPES and 27 mM NaHCO3. Plates containing cells in colla-
gen were incubated at 37°C in a humidified, 5% CO2 atmos-
phere for about 2 h until the collagen sets. DMEM (1.5 mL)
containing 10% FBS and forskolin (10 μM; Tocris Biosciences,
Bristol, UK) was added to each well and plates were placed
back in the incubator. Cells were replenished with fresh
DMEM medium supplemented with forskolin (10 μM) after
every 2 days until the end of day 12. Cells transformed into
cysts within 3 days of plating and were photographed using
an inverted microscope (Leica, Milton Keynes, UK) at ×100
magnification. On day 6, a total of 50 cysts each with a
diameter >50 μm were selected and referenced using micro-
scope slide-grids underneath each well. The same protocol
was followed for the transfected MDCK cells. To evaluate the
potential effect on cyst growth, naringenin (in a maximum
of 0.1% DMSO) at 1, 3, 10, 30, 60, 100 μM, or metformin
(10 μM; Sigma Aldrich, Poole, UK), or vehicle control (0.1%
DMSO) were added in DMEM (1.5 mL per well) containing
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forskolin (10 μM) on days 6, 8 and 10. Photographs of refer-
enced cysts were taken on days 6, 8, 10 and 12. Cyst area
(mm2) was measured using Image J software (v 1.4; Schneider
et al., 2012).
Electrophysiological measurements of
MDCK monolayers
MDCK cells were seeded onto Snapwell permeable supports
(0.4 μm pore, polyester membrane, 12 mm diameter, Costar
3801; Corning Inc, Corning, NY, USA) at 2 × 105 cells·cm−2.
Cells formed monolayers in culture in a humidified incubator
(37°C, 5% CO2). Culture medium was replaced every 2 days
and monolayers were used in experiments after 12–13 days in
culture. Monolayers were mounted in Ussing chambers and
bathed both sides with Krebs-Henselheit (KH) buffer: in mM,
NaCl 117, NaHCO3 25, KCl 4.7, MgSO4 1.2, KH2PO4 1.2,
glucose 11, CaCl2 2.5, bubbled with 95% O2/5% CO2 to main-
tain pH at 7.45. Experiments were performed at 37°C using
heated water-jacketed buffer reservoirs. The transepithelial
potential difference (Vt) generated across MDCK monolayers
was clamped to 0 mV and the short-circuit current (ISC)
recorded using a DVC-1000 voltage-clamp amplifier (World
Precision Instruments, New Haven, CT, USA) via an analog–
digital convertor (Bio-Pac MP100) and Acknowledge 3.8.2
software (Bio Pac Systems Inc., Goleta, CA, USA). Brief (2 s)
voltage steps from 0 to 1 mV were applied periodically and
the change in current used to calculate transepithelial resist-
ance. MDCK monolayers had a spontaneous Vt of −4.7 ±
1.3 mV on mounting, baseline ISC was 1.0 ± 0.3 μA·cm−2 and
transepithelial resistance was 2152 ± 308 Ωcm2 (n = 12).
siRNA TRPP2 transfection
MDCK cells were grown until 80% confluent. For transfection
experiments, cells were incubated overnight in reduced
serum medium Opti-MEM (31985; Life Technologies, Ltd.)
prior to transfection. Cells were then transfected with 20 nM
(final concentration per well) canine TRPP2 siRNA or scram-
bled control siRNA (Ambion Cy3-labeled siRNA; Invitrogen)
in a lipid-based transfection reagent lipofectamine 2000 (Inv-
itrogen) at 1:1000 dilution for 24 h. Cells were allowed to
recover in DMEM without antibiotics for 12 h. The following
day, cells were re-transfected using a similar procedure. This
double transfection procedure resulted in a transfection effi-
ciency of approximately 60–70%. Following transfection,
cells were grown for 24–48 h for Western blot analysis or
further processed for cyst culture or proliferation assay. Trans-
fection efficiency was monitored using confocal microscopy
of transfected cells cultured on chambered glass slides in
order to analyse siRNA subcellular localization and stability
(data not shown). The molecular target nomenclature for
TRPP2 (polycystin-2) conforms to BJP’s Concise Guide to
PHARMACOLOGY (Alexander et al., 2013).
Western blot analysis
Lysates of control and transfected cells were prepared in RIPA
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, 1 mM EDTA) with protease
inhibitor. Protein fractions (50 μg) were separated on 4–
12% Bis-Tris acrylamide gels, transferred to polyvinylidine
difluoride membranes and incubated in blocking buffer
(LiCor Biosciences, Lincoln, NE, USA) for 2 h and then over-
night at 4°C with anti-TRPP2 antibody (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA) or mouse monoclonal
anti-β-actin (AbCam, Cambridge, UK) in PBS. Blots were
washed three times in PBS/0.01% TWEEN 20 then incubated
with IR Dye anti-goat/mouse secondary antiserum (1:5000;
LiCor Biosciences) for 1 h, each at room temperature. Immu-
nostained proteins were visualized and quantified using an
infrared imaging system (Odyssey, LiCor Biosciences).
Data analysis and statistical procedures
Data are presented as mean and SEM from n independent
experiments Statistical tests were performed using Prism 5.0.4
(GraphPad Software) as stated in the text.
Chemicals
All materials used in this study were from Sigma Aldrich
unless otherwise specified.
Results
Naringenin inhibits growth of Dictyostelium
To identify the molecular mechanism of action of narin-
genin, we first defined conditions suitable for screening a
Dictyostelium REMI mutant library. The growth of wild-type
Dictyostelium in shaking cultures was reduced after 48–96 h
by naringenin with an EC50 between 50 and 100 μM
(Figure 2A). In contrast, development of Dictyostelium on
nitrocellulose filters (where starved cells aggregate and form
fruiting bodies) was unaffected in the presence of up to
200 μM naringenin (data not shown). This growth inhibition
enabled the selection of cells resistant to the effect of narin-
genin in shaking culture using a library of REMI mutants,
exposed to 200 μM naringenin for 21 days. Sequence analysis
of cells resistant to naringenin under these conditions iden-
tified 26 mutants containing an interrupted open reading
frame potentially controlling the effect of naringenin on
growth (Supporting Information Figure S1). One of these
interrupted genes, pkd2, encoded the TRPP2 protein
(DDB_G0272999). This protein showed a similar overall size
(82.2 kDa; 715 aa) to the human protein (variant 1; 87.0 kDa;
758 aa), with similar potential transmembrane domains (Sup-
porting Information Figure S2) although it showed low
homology to the human protein (26% identity, 49% similar-
ity; Supporting Information Figure S3).
TRPP2 mediates the effect of naringenin on
Dictyostelium
Recapitulation of the gene knockout mutant, pkd2−, in wild-
type cells (Supporting Information Figure S4) enabled the
comparison of the effect of naringenin on wild-type and
pkd2− cells. Initial analysis of these two cell lines showed that
100 μM naringenin caused a significant 37% reduction
(P < 0.001) in wild-type cell growth at 48 and 72 h (Support-
ing Informatioin Figure S5), whereas the pkd2− mutant
showed reduced growth compared with wild-type cells in the
absence of naringenin, but showed no significant change in
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growth in the presence of 100 μM naringenin at both time
points. To better quantify this resistant phenotype, and
because we have also shown the effect of a range of dietary
compounds on Dictyostelium cell behaviour (Robery et al.,
2011), we also examined a role for naringenin regulating cell
shape and movement. In these experiments, cells were devel-
oped under control conditions over a 5 h period, and then
treated with 200 μM naringenin for 60 min before recording
random cell movement. Naringenin treatment (compare Sup-
porting Information films S1 and S2) caused wild-type cells to
round up (Figure 2B; P < 0.001 comparing wild-type narin-
genin, untreated and treated), with a loss of pseudopod
formation (Figure 2C; P < 0.001 comparing wild-type narin-
genin, untreated and treated) and a block in cell movement
(Figure 2D; P < 0.01 comparing wild-type naringenin, un-
treated and treated). In contrast, the naringenin-treated
pkd2− mutant (see Supporting Information films S3 and S4)
showed no significant change in shape, measured as round-
ness (Figure 2B), did not form a significantly different
number of pseudopods (Figure 2C), and did not significantly
change cell movement (Figure 2D). These data suggest that
TRPP2 controls the function of naringenin on Dictyostelium
movement.
Naringenin inhibits growth of MDCK cells
and cysts
As mutations within the human TRPP2 protein are associated
with growth of renal cysts in polycystic kidney disease (PKD,
Chapin and Caplan, 2010), we next investigated a similar
effect of naringenin on the mammalian TRPP2 during cell
growth. TRPP2 is expressed in the MDCK canine kidney cell
line (Scheffers et al., 2000; 2002) and cyst formation in these
cells has been used as a model of PKD (Li et al., 2004; 2012).
In this system, naringenin inhibited the growth of MDCK
cells over 24–48 h (Figure 3) with EC50 values of 28.5 ± 1 μM
using two independent assays for cell growth assessment
(neutral red assay and SRB).
To investigate the relevance of this mechanism to cyst
formation, we then examined the effect of naringenin in
regulating the growth of cysts in this cell line over 6 days
Figure 2
Naringenin reduced growth of Dictyostelium and inhibited cell
behaviour, an effect controlled through the TRPP2 protein. (A) Dic-
tyostelium growth in liquid culture is reduced in a concentration-
dependent manner by naringenin. Ablation of the gene encoding
TRPP2 showed resistance to the effect of naringenin on cell behav-
iour, since incubating wild-type and pkd2− cells in 200 μM naringenin
(or vehicle control) for 1 h before recording and quantifying
cell behaviour over a 5 min period (see Supporting Information
Movies S1–S4), showed: (B) Naringenin-treated wild-type cells (blue
circles) significantly increased in circularity when compared with
vehicle controls (black circles). pkd2− mutant cells did not alter cell
shape following naringenin treatment cells. (C) Naringenin-treated
wild-type cells (blue circles) significantly decreased pseudopod for-
mation when compared with vehicle controls or pkd2− mutant cells;
and (D) Naringenin-treated wild-type cells (blue circles) significantly
reduced motility (measured by distance travelled) compared with
vehicle controls or pkd2− mutant cells. All data are shown from
quadruplicate independent experiments ± SEM.
◀
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(Figure 4). MDCK cells can be induced to form cysts by the
addition of forskolin (10 μM) to the growth medium bathing
a collagen gel inoculated with the cells. Following this treat-
ment, cysts were observed after 3 days, with individual cysts
reaching sizes of >50 μm in diameter 6 days after induction.
Addition of naringenin (1–100 μM) caused a concentration-
dependent decrease in cyst size, with an EC50 of 3–10 μM
following a 12 day treatment. Growth inhibition was com-
plete after 6 days exposure to 100 μM naringenin (12 days
post-induction); no cysts remained at this concentration.
Metformin (10 μM), an activator of AMP-dependent kinase,
also inhibited cyst growth, as reported in another study
(albeit at 1 mM over 20 days; Takiar et al., 2011).
Knockdown of TRPP2 (polycystin-2) protects
MDCK cysts and cells from naringenin
As it was clear that naringenin inhibited the proliferation of
MDCK cells and cysts, we implemented an siRNA strategy to
knock down the cellular level of TRPP2 in MDCK cells. In this
approach, cell extracts derived from MDCK in isolated cell
culture were analysed by Western blot and were positive for
TRPP2: two proteins (∼90 and ∼130 kDa) were detected as
shown previously (Wang et al., 2012). Transforming these
cells with siRNA specific to TRPP2 RNA or with a scrambled
sequence, and leaving cells to recover for up to 48 h, enabled
the assessment of reduced MDCK protein by Western blot
analysis. This approach gave a dose-dependent decrease in
the abundance of both TRPP2 proteins using specific TRPP2
siRNA at 10 nmol (TRPP2 + scrambled siRNA) or 20 nmol
(TRPP2 siRNA only; P < 0.05 and P < 0.001, n = 5 respec-
tively). Protein abundance was decreased (compared with
untransfected cells) to 56 ± 5% with 20 nmol of TRPP2 siRNA
after 24 h, 39 ± 8% after 48 h, and 32 ± 2% after 12 days
(Figure 5).
Figure 3
Inhibition of proliferating, unpolarized MDCK cell growth by narin-
genin after 48 h. Cell viability was measured using the neutral red
assay and the SRB protein assay. Data are from three independent
experiments showing mean and SEM (error bars not shown for SRB
for clarity). EC50 values were calculated by non-linear regression
(Graph Pad Prism 5). EC50 values were 28 ± 1 μM (neutral red assay)
and 29 ± 1 μM (SRB assay). R values were >0.98.
Figure 4
Inhibition of cyst growth by naringenin. (A) Photomicrographs of normal cysts treated from day 6 to day 12 with medium (control), 0.1% DMSO
(vehicle control), naringenin 1–100 μM or metformin 10 μM. The shadows/lines in some images are the gridlines used to identify the positions
of the cysts. Scale bar is 50 μm. (B) Plot of cyst size versus treatment. Naringenin inhibited cyst growth in a concentration-dependent manner.
Metformin (10 μM) inhibited cyst growth as expected. Data are from three independent experiments showing mean and SEM.
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The growth of MDCK cells transfected with either scram-
bled siRNA or TRPP2 siRNA was then measured in the pres-
ence of increasing concentrations of naringenin for 48 h. The
inhibitory effect of naringenin on growth was reduced in cells
transfected with TRPP2 siRNA (Figure 6) when compared
with untransfected cells and to cells transfected with scram-
bled siRNA. The EC50 value for naringenin was increased from
28 ± 1 μM (as in Figure 3) to 65 ± 1 μM. Transfection with
scrambled siRNA had no effect on the EC50 for growth inhi-
bition (30 μM). Thus, at a time point (48 h), when TRPP2
protein was reduced to 39% of control (Figure 5), the effect of
naringenin on cell growth was blunted and the EC50 value
more than doubled.
Untransfected MDCK cells and cells transfected with
TRPP2 siRNA, were then grown as cysts for 6 days after which
naringenin (1–100 μM) was added for another 6 days (until
day 12). Transfected cysts with knocked down TRPP2 were
larger (both control and vehicle) than their untransfected
counterparts, showing that reduced functional TRPP2 levels
promotes cyst formation and growth. Transfected cysts were
more resistant than control cysts (Figure 7C) to inhibition by
naringenin at 10 μM and 30 μM after 6 days (at day 12).
Naringenin at 100 μM progressively reduced cyst growth and
cysts were absent at 12 days. Metformin (10 μM) also inhib-
ited the growth of transfected cysts with no difference in
activity compared with normal cysts, confirming the selec-
tivity of TRPP2 siRNA treatment (Figure 7B).
Lack of effect of naringenin on chloride
secretion in MDCK monolayers
Naringenin has been reported to inhibit chloride secretion
(in rat colon) at super-physiological concentrations (EC50
> 330 μM; Collins et al., 2011), while others have reported
that it stimulates chloride secretion (Yang ZH et al., 2008). A
reduction in cAMP-dependent chloride secretion is one
method for reducing cyst growth (Li et al., 2004). We there-
fore performed experiments to determine the effect of narin-
genin on forskolin-induced chloride secretion measured as ISC
(Figure 8). Monolayers were treated on both sides with nar-
ingenin (30 μM) or its vehicle (0.1% DMSO) followed by
forskolin (20 μM, both sides). Forskolin increased ISC by 10.6
± 3.1 μA·cm−2 (mean ± SEM, n = 6) in vehicle-treated mon-
olayers, and by 11.6 ± 3.8 μA·cm−2 (n = 6) in naringenin-
treated monolayers, with no significant difference between
the means (P < 0.05, one-way ANOVA). Ten minutes after addi-
tion of forskolin, ISC remained similar in vehicle-treated mon-
olayers (2.0 ± 0.4 μA·cm−2, n = 6) and naringenin-treated
monolayers (2.1 ± 0.5 μA·cm−2, n = 6, P < 0.05, one-way
ANOVA). Furosemide, an inhibitor of basolateral chloride
uptake, added after the forskolin response began to decline,
had little or no effect on ISC, indicating that the stimulation of
chloride secretion by forskolin was transient in these cells.
Figure 5
Knockdown of TRPP2 (PC-2) protein in MDCK cells. (A) Representative Western blot of TRPP2 from cells transfected 48 h (lanes 1–3) or 12 days
(lanes 4–5). Lane 1: untransfected cells (48 h), Lane 2: cells transfected with scrambled siRNA (48 h), Lane 3: cells transfected with TRPP2 siRNA
(48 h), Lane 4: untransfected cells (12 days), Lane 5: cells transfected with TRPP2 siRNA (12 days). M: molecular marker. Sample loading
concentration 30 μg per lane. (B) Bands of TRPP2/β-actin fluorescence normalized to untransfected cells. Data are shown as mean ± SEM, n = 3–5.
*P > 0.05 relative to day-matched control.
Figure 6
Reduced inhibition of MDCK cell growth transfected with TRPP2
siRNA by naringenin after 48 h. The growth of cells transfected with
scrambled siRNA and treated with naringenin was unaffected. Cell
viability was measured using the neutral red assay. Data are from
three independent experiments showing mean and SEM (error bars
not shown for clarity for control, untransfected cells).
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Discussion and conclusions
Naringenin inhibits Dictyostelium growth
via TRPP2
We show for the first time an inhibitory action of naringenin
on renal tubule cell growth and cyst formation and demon-
strate the involvement of TRPP2 in these processes. The iden-
tification of this effect and mechanism came from the use of
Dictyostelium as a model organism for pharmacogenetics. In
our experiments, naringenin inhibited Dictyostelium growth
with an EC50 value of between 50 and 100 μM, higher than
the previously reported value of 20 μM (Russ et al., 2006).
Naringenin attenuated cell behaviour (shape, pseudopod
formation, random cell movement) after 60 min treatment.
The inhibitory effect of naringenin was conferred by the
expression of the TRPP2 protein, because the pkd2− mutant
was insensitive to naringenin-dependent reduction in cell
behaviour. In another study, other flavonoids (quercitin,
chrysin) including the related compound apigenin (4′,5,7-
trihydroxyflavone; naringenin is 4′,5,7-trihydroxyflavanone)
had no effect on Dictyostelium proliferation (Russ et al., 2006),
suggesting a degree of structural specificity for naringenin
presumably through a TRPP2-dependent effect.
Although a mechanism for how TRPP2 regulates Dictyos-
telium cell behaviour is unclear, a role for calcium signalling
in Dictyostelium has been reported before (Schlatterer and
Malchow, 1993; Unterweger and Schlatterer, 1995; Fache
et al., 2005). These studies showed that a decrease in extra-
cellular calcium levels instantly decreased cell speed and
induced a loss of cell attachment with the substratum caused
by loss of intracellular cell structure (Fache et al., 2005), con-
sistent with our findings of a naringenin-induced alteration
of cytoskeletal structure and block of cell behaviour. In addi-
Figure 7
Transfection with siRNA TRPP2 protects cysts from the growth-inhibitory effects of naringenin. (A) Photomicrographs of transfected cysts treated
from day 6 to day 12 with medium (control), 0.1% DMSO (vehicle control), naringenin 1–100 μM or metformin 10 μM. The shadows/lines in
some images are of the gridlines used to identify the positions of the cysts. Scale bar is 50 μm. (B) Plot of cyst size showing effect of medium
(control), DMSO 0.1% (vehicle control) or metformin (10 μM) on control and transfected cysts. (C) Plot of cyst size comparing effect of naringenin
in control and transfected cysts. Data are from three independent experiments showing mean and SEM. Data from control cysts are replotted from
Figure 4.
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tion, chelating intracellular calcium by loading with BAPTA
also prevented cell movement and pseudopod emission
(Schlatterer and Malchow, 1993; Unterweger and Schlatterer,
1995). The role of a potential pkd1 protein (TRPP1) in Dicty-
ostelium (DDB_G0289409) can also be considered in future
studies.
Naringenin inhibits renal cell growth
via TRPP2
Growth of renal MDCK cells and cysts was inhibited by
naringenin at similar EC50 values (cysts 10 μM, cells 28 μM)
to Dictyostelium (50 μM). We confirmed that TRPP2 was
expressed in MDCK cells and siRNA knockdown of this
protein indicated that TRPP2 also regulated the growth-
inhibitory action of naringenin in these mammalian cells.
Knockdown of TRPP2 in MDCK cells increased resistance to
the concentration of naringenin required to reduce cyst
growth.
TRPP2 has a number of roles in mammalian cells, and in
kidney tubule cells where it is most studied. TRPP2 or
polycystin-2 is a member of the TRP family of ion channels,
and is a Ca2+-permeable non-selective cation channel
(González-Perrett et al., 2001; Menè et al., 2013) located in
the endoplasmic reticulum (ER; Koulen et al., 2002) and in
the primary cilium (Abdul-Majeed and Nauli, 2011). Shear
stress bends the primary cilium and TRPP2 (bound in a
complex with TRPP1) admits Ca2+ into the cytoplasm. The
influx of Ca2+ stimulates Ca2+ release via TRPP2 on the ER and
elevates intracellular Ca2+ concentration, with important con-
sequences for growth. Ca2+ stimulates PDE and keeps cAMP
low, suppressing the Ras/Raf/MEK/ERK pathway of cyst pro-
liferation. When TRPP1 or TRPP2 is disrupted, as in muta-
tions of the corresponding genes PKD1 and PKD2 in PKD,
then flow-sensitive Ca2+ influx is reduced, cAMP is elevated
and the Ras/Raf/MEK/ERK pathway stimulated, leading to
cyst proliferation (Abdul-Majeed and Nauli, 2011).
We propose that naringenin may activate TRPP2 to cause
Ca2+ influx and a decrease in cellular proliferation. Narin-
genin has been shown to regulate other channels such as the
large conductance (BK) K+ channels in vascular myocytes
causing vasorelaxation (Saponara et al., 2006). The possibility
that naringenin binds and opens TRPP2, with downstream
growth-inhibitory effects, is therefore intriguing and novel.
The TRPP1/TRPP2 complex has other reported effects on
growth regulation, and through a diverse range of signalling
pathways in addition to Ca2+ and cAMP, for example: the
mammalian target of rapamycin (mTOR; to decrease cell size
and protein synthesis), STAT1/3 (to decrease cell growth and
division via p21/cdkc2 inhibition of the cell cycle), G-protein
regulated pathways of differentiation, apoptosis and prolif-
eration, and the β-catenin/Wnt pathway for gene expression
and differentiation (Chapin and Caplan, 2010). One interest-
ing mechanism is the binding of TRPP2 to the pro-
proliferative transcription factor, Id2. In this model of
ADPKD genesis, mutations to TRPP2 allow Id2 to enter the
nucleus and turn off growth-suppressive genes (Li et al.,
2005). A similar mechanism is proposed for TRPP2 in the
promotion of phospho-ERK-meditated eIF2α phosphoryla-
tion, which down-regulates cell growth (Liang et al., 2008).
The role(s) of these pathways in the actions of naringenin
requires further investigation.
It is important to note that naringenin was as potent at
inhibiting cyst growth as metformin and that the activity of
the latter was unaffected by the transfection procedure. Met-
formin activates AMPK, a kinase that controls growth and
metabolism, in part via the actions of mTOR, which is
required for growth (Takiar et al., 2011). In addition, AMPK
inhibits apical cystic fibrosis transmembrane conductance
regulator (CFTR) channels required for Cl− secretion (Takiar
et al., 2011; Li et al., 2012). Metformin therefore inhibits both
cystogenesis and chloride secretion and is a potential drug
development candidate for ADPKD.
Naringenin does not inhibit Cl− secretion
Other flavonoids (e.g. genistein and apigenin) modulate
CFTR-mediated transepithelial chloride secretion (Li et al.,
2004). However, while forskolin stimulated a transient
increase in ISC in MDCK cells, in agreement with a previous
report (Simmons, 1991), naringenin had no significant effect
Figure 8
Effect of naringenin on cAMP-dependent chloride secretion. (A) Rep-
resentative traces showing addition of naringenin (30 μM both sides)
or vehicle (DMSO 0.1% both sides), forskolin (20 μM, both sides)
and furosemide (100 μM, basolateral) on short-circuit current. (B)
Summary data (mean ± SEM, n = 6) of effect of naringenin (NG) on
forskolin-stimulated responses (peak and plateau, i.e. 10 min after
forskolin).
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on ISC or on the response to forskolin. These data indicate that
the reduction in cyst growth was not due to a reduction in
cAMP-dependent chloride secretion.
Currently there are no approved clinical therapies for the
treatment of PKD (Calvet, 2008; Takiar and Caplan, 2011).
Tolvaptan, a vasopressin V2 receptor antagonist, which is
used to reduce cAMP-dependent fluid secretion, reduced the
decline in kidney function in patients with ADPKD, but
adverse effects led to a high level of discontinuation (Torres
et al., 2012). Other more experimental strategies include inhi-
bition of CFTR by metformin or direct channel blockers
(again to prevent fluid secretion into cysts; Li et al., 2004;
Yang B et al., 2008; Takiar et al., 2011); inhibition of mTOR by
metformin (Takiar and Caplan, 2011) and inhibition of B-Raf
as the crucial point in the MEK/ERK pathway (Calvet, 2008;
Takiar and Caplan, 2011). Our results allow us to speculate
about a potential use for naringenin in ADPKD treatment. In
the minority (15%) of ADPKD patients where TRPP2 function
is lost, naringenin would presumably have no effect. In the
majority of ADPKD cases, where TRPP1 function is absent
(but TRPP2 is present), naringenin could potentially activate
TRPP2 to inhibit cyst growth in these patients, providing a
novel therapeutic approach for ADPKD treatment. Further
study of naringenin as a drug for the treatment of ADPKD is
now required.
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Figure S1 Dictyostelium REMI mutants identified in a growth
screen where cells were exposed to naringenin (200 μM)
over 21 days. Genes are identified by individual dictybase
identifier, gene name (where available) and potential protein
functions.
Figure S2 The Dictyostelium TRPP2 (polycystein-2) like
protein (DDB_G0272999) showed a similar domain structure
to the human TRPP2 protein, although it lacked a clearly
defined coiled-coil domain.
Figure S3 Alignment of TRPP2 proteins Dictyostelium and
humans. The Dictyostelium TRPP2 protein (DDB_G0272999),
human polycystic kidney disease 2-like 1 protein isoform 2
(Hs_TRPP3; NP_001240766) and human polycystic kidney
disease type II protein (Hs_TRPP2_V1; AAC16004) were
aligned using ClustalW. This alignment shows that the
N-terminal region of TRPP2 conserved in animal species and
associated with cilial targeting of the protein is not conserved
in the Dictyostelium protein (Geng L et al., 2006). The GSK-3
dependent phosphorylation site S76 (Streets et al., 2006), the
casine kinase 2 phosphorylation site at S812, responsible for
restricting protein localisation to the ER and cilia (Cai et al.,
2004), and the PKD-dependent phosphorylation site, S801
(Streets et al., 2010; all highlighted), are also not conserved in
the Dictyostelium protein.
Figure S4 The Dictyostelium pkd2− mutant was recapitulated
in wild-type cells by the construction of a knockout vector
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with the central coding region of the pkd2 gene replaced by a
blasticidin resistance cassette (BsR). Homologous integration
of this cassette into wild-type cells and screening by PCR for
genomic (G), Vector (V) and knockout (KO) PCR products
for the 5′ and 3′ targeting region identified independent
pkd2-mutants.
Figure S5 Ablation of Dictyostelium the pkd2 gene provides
resistance to naringenin during growth. Dictyostelium cells
grown in still culture over a 72 h period show reduced pro-
liferation in the presence of naringenin (100 μM). Ablation of
pkd2 slows growth in these cells under control conditions,
but cells do not show a further reduction in growth in the
presence of naringenin (100 μM) suggesting resistance to nar-
ingenin during growth.
Movie S1 Wild-type Dictyostelium cell movement. Dictyos-
telium wild-type (A×2) cells, were induced to chemotax by
repeated pulsing with cAMP over a 5 h period, and random
cell movement was monitored by time-lapse photography,
capturing one image every 15 s for 5 min. Cell behaviour was
quantified by computer-generated outlines that are used to
calculate average cell shape (circularity), protrusion forma-
tion and motility.
Movie S2 Wild-type Dictyostelium cell movement following
naringenin treatment. Dictyostelium wild-type (A×2) cells,
were induced to chemotax by repeated pulsing with cAMP
over a 5 h period, and then exposed to 200 mM naringenin
for 60 min, and random cell movement was monitored by
time-lapse photography, capturing one image every 15 s for
5 min. Cell behaviour was quantified by computer-generated
outlines that are used to calculate average cell shape (circu-
larity), protrusion formation and motility.
Movie S3 pkd2-Dictyostelium cell movement. Dictyostelium
wild-type (A×2) cells, were induced to chemotax by repeated
pulsing with cAMP over a 5 h period, and random cell move-
ment was monitored by time-lapse photography, capturing
one image every 15 s for 5 min. Cell behaviour was quantified
by computer-generated outlines that are used to calculate
average cell shape (circularity), protrusion formation and
motility.
Movie S4 pkd2-Dictyostelium cell movement following nar-
ingenin treatment. Dictyostelium wild-type (A×2) cells, were
induced to chemotax by repeated pulsing with cAMP over a
5 h period, and then exposed to 200 mM naringenin for
60 min, and random cell movement was monitored by time-
lapse photography, capturing one image every 15 s for 5 min.
Cell behaviour was quantified by computer-generated out-
lines that are used to calculate average cell shape (circularity),
protrusion formation and motility.
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